未登录

S

Serge Jabbour

university of texas system

H指数:35

被引数:5,323

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Role of the trigeminal system in pancreatic innervation: new concept and challenge - a narrative review

三叉神经系统在胰腺神经支配中的作用：新概念与挑战——一篇叙述性综述

Endocrine Research

IF1.8

2026-02-010

PRE

6-NITRODOPAMINE IS A MAJOR MEDIATION THAT POTENTIATES CONTRACTIONS OF HUMAN ISOLATED EPIDIDYMAL VAS DEFERENS INDUCED BY NORADRENALINE AND ELECTRIC FIELD STIMULATION

JOURNAL OF SEXUAL MEDICINE

IF3.3

2024-12-050

PRE

Two- versus one-bag fluid delivery in pediatric and adolescent diabetic ketoacidosis: a systematic review and meta-analysis

CLINICAL AND EXPERIMENTAL PEDIATRICS

IF3.6

2024-10-150

OAAI

Switching to Tirzepatide 5 mg From Glucagon-Like Peptide-1 Receptor Agonists: Clinical Expectations in the First 12 Weeks of Treatment

ENDOCRINE PRACTICE

IF4.6

2024-08-012

OAAI

Continuous Glucose Monitoring Profiles and Health Outcomes After Dapagliflozin Plus Saxagliptin vs Insulin Glargine

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

IF5.1

2024-02-270

OA

Physicians' Considerations and Practice Recommendations Regarding the Use of Sodium-Glucose Cotransporter-2 Inhibitors

医生关于使用钠-葡萄糖Cotransporter-2抑制剂的考虑和实践建议

JOURNAL OF CLINICAL MEDICINE

IF2.9

2022-10-137

OAAI

Herpes Zoster Incidence and Burden in Adults With Type 2 Diabetes in the US: A Retrospective Database Analysis

美国成人2型糖尿病患者的带状疱疹发病率和负担: 一项回顾性数据库分析

IF16.6

2022-09-235

OAAI

Sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice

DIABETES OBESITY & METABOLISM

IF5.7

2022-03-3027

OAAI

Flash glucose monitoring in type 2 diabetes managed with basal insulin in the USA: a retrospective real-world chart review study and meta-analysis

BMJ OPEN DIABETES RESEARCH & CARE

IF4.1

2022-01-2049

OAAI

Meta-analysis of Two Real-World Chart Review Studies to Determine the Effectiveness of FreeStyle Libre Flash Glucose Monitoring System on HbA1c in Adults with Type 2 Diabetes Managed with Basal Insulin

IF7.5

2021-06-010

PRE

Glucose Control after Initiation of Flash Glucose Monitoring in Type 2 Diabetes Managed with Basal Insulin: A Retrospective Real-World Chart Review Study from the US

IF7.5

2021-06-014

PRE

Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial

IF16.6

2020-08-1839

OAAI

Incidence of Herpes Zoster in Patients with Type 2 Diabetes and Consequences for Treatment

IF7.5

2020-06-010

PRE

Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, Phase 3 trial

DIABETES OBESITY & METABOLISM

IF5.7

2020-02-237

OAAI

Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes

艾塞那肽和达格列净联合改善2型糖尿病患者肝脂肪变性和纤维化标志物

DIABETES OBESITY & METABOLISM

IF5.7

2019-12-1457

OAAI

Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION-8 study

DIABETES OBESITY & METABOLISM

IF5.7

2019-10-088

PREAI

Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial

IF16.6

2019-06-0410

OAAI

Exenatide Once-Weekly in Diabetes Patients with Stage 2/3 Chronic Kidney Disease-A Pooled 6-Month Analysis

IF7.5

2019-06-010

PRE

Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial

IF16.6

2018-08-0670

OAAI

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial

IF16.6

2018-07-19200

OAAI